Developer docs
API playgroundTry for free, no card

Search company profiles

Arkea Bio

Full company profile

uuid00003oh

Namestring
Arkea Bio
Legal namestring
ArkeaBio Corp.
Websiteurl
arkeabio.com
Company typeenum
Private
Founded yearint
2022
Descriptiontext

Arkea Bio (legal entity ArkeaBio Corp.) is a U.S.-based agricultural bioscience company founded in 2022 and headquartered in Charlestown, Massachusetts. The company is developing a first-of-its-kind methane-reducing vaccine for cattle that stimulates the animal's immune system to produce antibodies against methane-producing microbes in the rumen, reducing enteric emissions without disrupting digestion or affecting meat or milk quality. Early trials have demonstrated 10-15% methane reduction with a stated pathway to greater than 40%, and the technology is positioned as non-GMO, organic-compatible, and uniquely scalable to the roughly 80% of the world's 1.2 billion cattle that are raised on pasture where feed-additive solutions cannot reach.

Arkea Bio is a single-product company in the pre-revenue stage, with commercialization planned to begin via farmer pilot programs in 2026-2027 ahead of a commercial launch before 2030. The company plans to monetize through vaccine sales to farmers and ranchers, potentially bundled with carbon-credit programs, payments for verified emissions reductions, and premium pricing for low-carbon beef and dairy in eco-conscious markets. Its target customer segments span farmers and ranchers, governments and policymakers, food producers and consumer brands (for Scope 3 emissions reductions), and end consumers of sustainable animal protein.

The business is venture-backed, with $40+ million raised across a $12 million seed (December 2022), a $26.5 million Series A (May 2024), and a $7 million Series A1 (September 2025), with Breakthrough Energy Ventures leading every round and AgriZeroNZ co-leading the most recent. The go-to-market motion is enterprise B2B, leveraging existing animal vaccine manufacturing and agricultural distribution infrastructure, and the company cites an addressable market estimated at more than $15 billion for cattle methane reduction. Strategic supporters include Fonterra, whose Chief Science & Technology Officer has publicly endorsed the technology's potential as a climate breakthrough.

Short descriptiontext

Arkea Bio is a U.S. agricultural bioscience company developing a first-of-its-kind vaccine that reduces methane emissions from cattle by stimulating antibodies against rumen microbes, serving farmers, food producers, governments, and consumers ahead of a pre-2030 commercial launch.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersCharlestown, United States
HQ citystring
Charlestown
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
methane vaccine, livestock emissions, agricultural biotechnology, cattle vaccine, enteric methane reduction
Industry4 codes
PRIMARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAIAEAH
Veterinary Vaccines
SECONDARYAFACALAA
Vaccination & Immunization Programs (Herd/Flock Health Protocols)
Agriculture & Food Production/Agricultural Services (Custom Farming, Agronomy, Veterinary)/Animal Health Services (Vaccination Programs, Biosecurity, Parasite Control)
NAICS code1 code
  • Support Activities for Animal Production11521
SIC code1 code
  • Agricultural Services700
Product category
Livestock Methane-Reduction Vaccine
Social media profiles2 records
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Methane-Reducing Vaccine Sales
TypeOne Time License
Description

Pre-revenue company developing a vaccine to reduce livestock methane emissions. The company plans to generate revenue through vaccine sales to farmers, potentially bundled with carbon credit programs. Revenue will also come from payments for emissions reductions and premium pricing in sustainable meat and dairy markets.

vcaonline.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Arkea Bio is developing a first-of-its-kind methane-reducing vaccine for cattle that triggers the animal's immune system to generate antibodies against methane-producing microbes in the rumen, lowering enteric methane emissions without disrupting digestion or harming the animal. The vaccine is positioned as a scalable, non-GMO, organic-compatible alternative to feed additives, designed to integrate with routine veterinary care and existing farm practices for commercial deployment ahead of 2030.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 10-15% methane reduction in early trials, with potential to reach >40% as formulation optimizations continue
+4 more records
Product overview1 text field

Arkea Bio is a single-product company pioneering the development of a methane-reducing vaccine for cattle. Their core offering is a first-of-its-kind immunological solution that targets methane-producing microbes in the rumen of cattle, activating a natural immune response to reduce emissions without disrupting digestion. The company is advancing from current animal studies toward expanded field programs in 2026-2027, with commercial launch targeted before 2030.

Product and service1 record
1Methane-Reducing Vaccine for Cattle
CategoryLivestock methane-reduction vaccine
Description

A first-of-its-kind vaccine that stimulates cattle immune systems to produce antibodies targeting methane-producing microbes in the rumen, reducing enteric methane emissions without disrupting digestion or affecting meat or milk quality. The vaccine is positioned as scalable to all the world's 1.2 billion cattle, cost-effective at under $100 per ton of emissions reduction, and compatible with organic farming.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Mootral develops a garlic-and-citrus feed additive that reduces enteric methane emissions from cattle. It targets the same problem as ArkeaBio — lowering methane from beef and dairy herds — but uses a feed-based mechanism rather than an immunological vaccine, making it a directly comparable alternative solution.

TypeDirect peer
Description

CH4 Global commercializes Asparagopsis-based seaweed feed supplements to reduce enteric methane in cattle and sheep. Like ArkeaBio, it is pursuing large-scale methane abatement for livestock, positioning it as a directly competing approach to the same farmer and food-producer customers.

TypeDirect peer
Description

Symbrosia produces an Asparagopsis seaweed feed additive (SeaGraze) targeting enteric methane reduction in dairy and beef cattle. It is a direct competitor to ArkeaBio's vaccine in the livestock methane-reduction category, aimed at the same enterprise customers and emissions outcome.

TypeDirect peer
Description

Blue Ocean Barns develops Asparagopsis-based feed supplements for ruminants to cut enteric methane. It is directly comparable to ArkeaBio as an emerging methane-mitigation solution targeting dairy and beef producers and the carbon-credit value chain.

5Zelp
TypeDirect peer
Description

Zelp has developed a wearable methane-capturing mask/halter for cattle that oxidizes eructed methane. It addresses the same core problem as ArkeaBio — reducing cattle methane — but through a hardware/device solution, making it a directly comparable alternative for the same dairy and beef customers.

TypeDirect peer
Description

Rumin8 develops seaweed and red-algae derived feed supplements to reduce enteric methane in cattle. It is a direct peer to ArkeaBio in the livestock methane-reduction space, pursuing the same enterprise customers (farmers, food brands, governments) with a feed-additive alternative to vaccines.

TypeDirect peer
Description

Impetus Agriculture is developing a feed-additive product targeting enteric methane emissions in cattle. It is a directly comparable emerging player addressing the same problem and customer base as ArkeaBio, with a different (feed-based) delivery mechanism.

TypeBroad incumbent
Description

dsm-firmenich has commercialized Bovaer (3-NOP), a feed additive that reduces enteric methane in dairy cattle and is being rolled out with partners globally. As a major animal nutrition and health incumbent, it competes with ArkeaBio's vaccine in the same methane-reduction category but with established scale, regulatory approvals, and global distribution.

TypeBroad incumbent
Description

Elanco is a large animal health company that has partnered with dsm-firmenich to commercialize Bovaer for the US market and offers a broad portfolio of livestock products. It competes with ArkeaBio in the methane-reduction space while bringing established veterinary sales channels, manufacturing, and regulatory expertise to the category.

TypeBroad incumbent
Description

Alltech is a global animal nutrition and health company with a broad portfolio including methane-mitigation feed technologies (e.g., Yea-Sacc, Egalis). It is a broad incumbent that overlaps with ArkeaBio's mission of reducing livestock emissions and competes for the same farmer and food-produyer customers.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors6 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arkea Bio

Livestock Methane-Reduction Vaccinearkeabio.com

Arkea Bio is a U.S. agricultural bioscience company developing a first-of-its-kind vaccine that reduces methane emissions from cattle by stimulating antibodies against rumen microbes, serving farmers, food producers, governments, and consumers ahead of a pre-2030 commercial launch.

What Arkea Bio does

Arkea Bio (legal entity ArkeaBio Corp.) is a U.S.-based agricultural bioscience company founded in 2022 and headquartered in Charlestown, Massachusetts. The company is developing a first-of-its-kind methane-reducing vaccine for cattle that stimulates the animal's immune system to produce antibodies against methane-producing microbes in the rumen, reducing enteric emissions without disrupting digestion or affecting meat or milk quality. Early trials have demonstrated 10-15% methane reduction with a stated pathway to greater than 40%, and the technology is positioned as non-GMO, organic-compatible, and uniquely scalable to the roughly 80% of the world's 1.2 billion cattle that are raised on pasture where feed-additive solutions cannot reach.

Arkea Bio is a single-product company in the pre-revenue stage, with commercialization planned to begin via farmer pilot programs in 2026-2027 ahead of a commercial launch before 2030. The company plans to monetize through vaccine sales to farmers and ranchers, potentially bundled with carbon-credit programs, payments for verified emissions reductions, and premium pricing for low-carbon beef and dairy in eco-conscious markets. Its target customer segments span farmers and ranchers, governments and policymakers, food producers and consumer brands (for Scope 3 emissions reductions), and end consumers of sustainable animal protein.

The business is venture-backed, with $40+ million raised across a $12 million seed (December 2022), a $26.5 million Series A (May 2024), and a $7 million Series A1 (September 2025), with Breakthrough Energy Ventures leading every round and AgriZeroNZ co-leading the most recent. The go-to-market motion is enterprise B2B, leveraging existing animal vaccine manufacturing and agricultural distribution infrastructure, and the company cites an addressable market estimated at more than $15 billion for cattle methane reduction. Strategic supporters include Fonterra, whose Chief Science & Technology Officer has publicly endorsed the technology's potential as a climate breakthrough.

Arkea Bio firmographics

Firmographics
Name
Arkea Bio
Legal name
ArkeaBio Corp.
Website
https://arkeabio.com
Company type
Private
Founded year
2022
Operating status
Operating
Headcount range
11–50 employees
Short description
Arkea Bio is a U.S. agricultural bioscience company developing a first-of-its-kind vaccine that reduces methane emissions from cattle by stimulating antibodies against rumen microbes, serving farmers, food producers, governments, and consumers ahead of a pre-2030 commercial launch.
Ownership category
akta.pro rank

Arkea Bio industry classification

Industry
Product category
Livestock Methane-Reduction Vaccine
NAICS
Support Activities for Animal Production (11521)
SIC
Agricultural Services (700)
akta.pro industry
PRIMARYHLAMAKAH
Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA)
SECONDARYHLAMAEAL
Veterinary Vaccines (Biologics)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
SECONDARYHLAIAEAH
Veterinary Vaccines
SECONDARYAFACALAA
Vaccination & Immunization Programs (Herd/Flock Health Protocols)
Agriculture & Food Production/Agricultural Services (Custom Farming, Agronomy, Veterinary)/Animal Health Services (Vaccination Programs, Biosecurity, Parasite Control)

Keywords

  • Methane vaccine
  • Livestock emissions
  • Agricultural biotechnology
  • Cattle vaccine
  • Enteric methane reduction

Where Arkea Bio is headquartered

Location

Headquarters

HQ city
Charlestown
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Arkea Bio business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

  1. Methane-Reducing Vaccine Sales: Pre-revenue company developing a vaccine to reduce livestock methane emissions. The company plans to generate revenue through vaccine sales to farmers, potentially bundled with carbon credit programs. Revenue will also come from payments for emissions reductions and premium pricing in sustainable meat and dairy markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Arkea Bio product offering

Product offering

Core offering

Arkea Bio is developing a first-of-its-kind methane-reducing vaccine for cattle that triggers the animal's immune system to generate antibodies against methane-producing microbes in the rumen, lowering enteric methane emissions without disrupting digestion or harming the animal. The vaccine is positioned as a scalable, non-GMO, organic-compatible alternative to feed additives, designed to integrate with routine veterinary care and existing farm practices for commercial deployment ahead of 2030.

Product overview

Arkea Bio is a single-product company pioneering the development of a methane-reducing vaccine for cattle. Their core offering is a first-of-its-kind immunological solution that targets methane-producing microbes in the rumen of cattle, activating a natural immune response to reduce emissions without disrupting digestion. The company is advancing from current animal studies toward expanded field programs in 2026-2027, with commercial launch targeted before 2030.

Differentiator

Problem solved

Functional benefit

Products and services

  • Methane-Reducing Vaccine for Cattle A first-of-its-kind vaccine that stimulates cattle immune systems to produce antibodies targeting methane-producing microbes in the rumen, reducing enteric methane emissions without disrupting digestion or affecting meat or milk quality. The vaccine is positioned as scalable to all the world's 1.2 billion cattle, cost-effective at under $100 per ton of emissions reduction, and compatible with organic farming.

Quantifiable outcome

  • 10-15% methane reduction in early trials, with potential to reach >40% as formulation optimizations continue
  • +4 more outcomes

Companies that use Arkea Bio

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Arkea Bio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Arkea Bio partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Arkea Bio competitors and assessment

Company assessment

Direct peers

  • Mootral: Mootral develops a garlic-and-citrus feed additive that reduces enteric methane emissions from cattle. It targets the same problem as ArkeaBio — lowering methane from beef and dairy herds — but uses a feed-based mechanism rather than an immunological vaccine, making it a directly comparable alternative solution.
  • CH4 Global: CH4 Global commercializes Asparagopsis-based seaweed feed supplements to reduce enteric methane in cattle and sheep. Like ArkeaBio, it is pursuing large-scale methane abatement for livestock, positioning it as a directly competing approach to the same farmer and food-producer customers.
  • Symbrosia: Symbrosia produces an Asparagopsis seaweed feed additive (SeaGraze) targeting enteric methane reduction in dairy and beef cattle. It is a direct competitor to ArkeaBio's vaccine in the livestock methane-reduction category, aimed at the same enterprise customers and emissions outcome.
  • Blue Ocean Barns: Blue Ocean Barns develops Asparagopsis-based feed supplements for ruminants to cut enteric methane. It is directly comparable to ArkeaBio as an emerging methane-mitigation solution targeting dairy and beef producers and the carbon-credit value chain.
  • Zelp: Zelp has developed a wearable methane-capturing mask/halter for cattle that oxidizes eructed methane. It addresses the same core problem as ArkeaBio — reducing cattle methane — but through a hardware/device solution, making it a directly comparable alternative for the same dairy and beef customers.
  • Rumin8: Rumin8 develops seaweed and red-algae derived feed supplements to reduce enteric methane in cattle. It is a direct peer to ArkeaBio in the livestock methane-reduction space, pursuing the same enterprise customers (farmers, food brands, governments) with a feed-additive alternative to vaccines.
  • Impetus Agriculture: Impetus Agriculture is developing a feed-additive product targeting enteric methane emissions in cattle. It is a directly comparable emerging player addressing the same problem and customer base as ArkeaBio, with a different (feed-based) delivery mechanism.

Broad incumbents

  • dsm-firmenich: dsm-firmenich has commercialized Bovaer (3-NOP), a feed additive that reduces enteric methane in dairy cattle and is being rolled out with partners globally. As a major animal nutrition and health incumbent, it competes with ArkeaBio's vaccine in the same methane-reduction category but with established scale, regulatory approvals, and global distribution.
  • Elanco Animal Health: Elanco is a large animal health company that has partnered with dsm-firmenich to commercialize Bovaer for the US market and offers a broad portfolio of livestock products. It competes with ArkeaBio in the methane-reduction space while bringing established veterinary sales channels, manufacturing, and regulatory expertise to the category.
  • Alltech: Alltech is a global animal nutrition and health company with a broad portfolio including methane-mitigation feed technologies (e.g., Yea-Sacc, Egalis). It is a broad incumbent that overlaps with ArkeaBio's mission of reducing livestock emissions and competes for the same farmer and food-produyer customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key highlights6 records

Customer concentration

Arkea Bio social profiles

Digital presence

Arkea Bio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arkea Bio leadership team

Management profile

Number of profiles

Profiles8 records

Arkea Bio funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arkea Bio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arkea Bio

What does Arkea Bio do?

Arkea Bio is developing a first-of-its-kind methane-reducing vaccine for cattle that triggers the animal's immune system to generate antibodies against methane-producing microbes in the rumen, lowering enteric methane emissions without disrupting digestion or harming the animal. The vaccine is positioned as a scalable, non-GMO, organic-compatible alternative to feed additives, designed to integrate with routine veterinary care and existing farm practices for commercial deployment ahead of 2030.

Is Arkea Bio a public or private company?

Arkea Bio is a private company. It is classified as venture growth investor backed and is currently operating.

When was Arkea Bio founded?

Arkea Bio was founded in 2022. It employs 11 to 50 people.

Where is Arkea Bio based?

Arkea Bio is headquartered in Charlestown, United States, in the North America region.

How does Arkea Bio make money?

One revenue line is on record: methane-Reducing Vaccine Sales.

Who are Arkea Bio's main competitors?

Direct peers on record are Mootral, CH4 Global, Symbrosia, Blue Ocean Barns, Zelp, Rumin8 and Impetus Agriculture. Broad incumbents are dsm-firmenich, Elanco Animal Health and Alltech.

Does Arkea Bio have an API?

No public API is recorded for Arkea Bio.

What industry is Arkea Bio in?

Arkea Bio's product category is Livestock Methane-Reduction Vaccine. Its primary akta.pro industry code is HLAMAKAH, Vaccine Technology Platforms (Live, Inactivated, Subunit, Vector, mRNA/DNA), with a secondary code of HLAMAEAL, Veterinary Vaccines (Biologics). Its NAICS code is 11521 and its SIC code is 700.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooNew Zealand effort to reduce livestock emissions revives mRNA vaccine falsehoodsNew Zealand's AgriZero invested in US startup ArkeaBio's methane-reducing vaccine for cattle, but the vaccine uses recombinant protein technology, not mRNA. The company's CEO said it delivers only protein and does not alter animal DNA, refuting online falsehoods.FinSMEsArkeaBio Raises $7M in Series A1 FundingArkeaBio, a Boston-based agricultural bioscience company, raised $7M in Series A1 funding co-led by Breakthrough Energy Ventures and AgriZeroNZ. The round brings total funding to over $40M, to be used for R&D, farmer pilot programs, and operations. The company plans to expand into field programs in 2026-2027.PomegraArkeaBio Raises $15M Series A2 for Methane VaccineArkeaBio raised a $15M Series A2 led by AgriZeroNZ with Breakthrough Energy Ventures, cutting about one-third of its staff. The cattle methane vaccine targets a 10-15% reduction, with regulatory filing expected in 2027 and launch in 2028.TechStartupsStartup Funding News Today, September 30, 2026: General Intuition, Gravity, Zenithon, ArkeaBio & MoreOn September 30, 2026, startups raised roughly $280.6 million in dollar-denominated capital, led by General Intuition's $220 million at a $6.2 billion valuation. Other rounds included ArkeaBio's $15 million for a methane vaccine and Gravity's $15 million for home-interiors infrastructure. The funding reflects bets on proprietary data and domain-specific AI.BitlyExclusive: ArkeaBio raises $15m for livestock methane tech, cuts headcountArkeaBio raised $15 million in a Series A2 round led by AgriZeroNZ and Breakthrough Energy, and cut headcount by about a third. The vaccine targets rumen methanogens to cut livestock methane, with a first product aiming for 10-15% reduction. The company expects to submit a regulatory application next year and commercialize in 2028.AgFunderNewsExclusive: ArkeaBio raises $15m for livestock methane tech, cuts headcountArkeaBio raised $15 million in a Series A2 round led by AgriZeroNZ and Breakthrough Energy, and cut headcount by about a third. The vaccine targets rumen methanogens to reduce livestock methane by 10-15% initially, with commercialization expected in 2028.VenturecapitaltrackerArkeaBio Raises $15M Series A2 for Methane VaccineArkeaBio raised a $15M Series A2 led by AgriZeroNZ to advance its livestock methane vaccine toward New Zealand approval and a 2028 launch. The company reduced headcount by about one-third and targets a 10-15% methane reduction. Investors will need evidence on repeatable efficacy and cost per tonne avoided.AgribusinesswireArkeaBio Raises $15M for Livestock Methane Vaccine, Cuts StaffArkeaBio raised $15 million in a Series A2 led by AgriZeroNZ and cut about a third of its staff. The Boston-based startup targets a 10-15% methane reduction in dairy cattle, with a New Zealand regulatory filing expected next year and commercialization planned for 2028.SecSEC FORM DArkea Bio Corp., a Delaware-incorporated technology company founded in 2021 and headquartered in Charlestown, Massachusetts, filed a Form D notice with the SEC on October 14, 2025, for an exempt offering of equity securities under Rules 506(b) and 506(c). The filing indicates a total offering amount of $12,000,017 USD, with $6,999,999 already sold to 2 investors as of the first sale on September 26, 2025, leaving $5,000,018 remaining to be sold.AgFunderNewsArkeaBio raises $7m, hires Vence cofounder to accelerate vaccine for livestock methane reductionArkeaBio raised $7 million in a Series A+ round and hired Frank Wooten as CEO, with Dr. Colin South moving to chief business officer. The funding will advance the vaccine from animal studies to full field trials in 2026-2027. The vaccine targets methanogens in ruminant rumen to reduce methane emissions.